Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD200R1L drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD200R1L ECD-Fc Fusion Protein (High purity >95%, Endotoxin <1EU/μg. Sequence Verified, HEK293 expressed. Native glycosylation.) | View CD200R1L Products |
| Gene Delivery | CD200R1L Lentivirus Premade Particles (Full-length ORF for stable cell line construction; puromycin selection; endotoxin controlled.) | View CD200R1L Products |
| Benchmark Ab | Anti-CD200R1L Reference Antibody (Research-grade recombinant positive control for binding assays.) | View CD200R1L Products |
| Validator | CD200R1L siRNA Set (3 unique sequences for knockdown verification and specificity control.) | View CD200R1L Products |
| Related Target A | CD200 (Endogenous ligand for interaction profiling.) | View CD200 Products |
| Related Target B | CD200R1 (Paralog receptor with high ECD homology; critical for off-target counter-screening.) | View CD200R1 Products |
| Related Target C | DAP12 (TYROBP) (Intracellular signaling adaptor for functional assay development.) | View DAP12 Products |
Critical Assay Challenges & Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily selectivity (CD200R1 vs CD200R1L) | Homolog panel proteins available, strict Sequence Verified identity and >95% purity. |
| Cross-species evaluation (Human/Mouse/Cyno) | Ortholog proteins available with >95% purity; mass spec verified for assay consistency. |
| Functional membrane conformation | Lentivirus for Stable Cell Line generation, essential for preserving native cell-surface structure. |
| Lack of Controls | Recombinant control antibodies included for reliable assay baselines. |
| False Positives / Specificity | Sequence-verified siRNA included for strict specificity and background checks. |
Live CD200R1L R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Molecular Characteristics of CD200R1L
CD200R1L (also known as CD200RLa) is a type I transmembrane glycoprotein belonging to the CD200 receptor family. Its extracellular region contains two immunoglobulin-like domains: an Ig-like V-type domain (membrane-distal) and an Ig-like C2-type domain (membrane-proximal), as annotated in UniProt Q6Q8B3. A naturally occurring missense variant (rs4682119) is documented in dbSNP, which may affect receptor-ligand interactions or signaling. The receptor lacks classical inhibitory motifs and instead pairs with the ITAM-containing adaptor DAP12 (TYROBP) to transduce activating signals in myeloid cells.
Global Clinical Landscape & Future Outlook
The exploration of CD200R1L as a therapeutic target is gaining early-stage momentum. As an activating receptor that pairs with DAP12 (in contrast to the inhibitory CD200R1), it presents a unique opportunity to modulate myeloid cell activity. While CD200R1 has entered clinical trials, CD200R1L remains an emerging target with potential in both immuno-oncology and autoimmune diseases. The next wave of R&D is targeting novel activating receptors on macrophages and dendritic cells to overcome tumor microenvironment suppression or to temper overactive immune responses. Key differentiation requirements include exquisite selectivity over CD200R1 (high ECD homology ~70%) and careful assessment of cross-species reactivity for preclinical models.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (Agonist/Antagonist) | Early-stage Biotechs, Academic Spin-offs | Solid Tumors, Autoimmunity | Selectivity Assay (Need High-Purity ECD-Fc to distinguish from CD200R1) |
| Fc-Enhanced mAb | Immuno-Oncology Focused Biotech | Hematologic Malignancies | ADCC Reporter Assay (Need high-purity target antigen) |
| Bispecific Antibodies | Platform Technology Companies | Cold Tumors, Immunotherapy | Cross-reactivity Binding (Need Human/Cyno/Mouse orthologs and precise ECDs) |
| Cell Therapy (Engineered Macrophages) | Advanced Therapies | Refractory Cancers | Signaling Validation (Need Lentivirus for DAP12 co-expression) |